Last updated: September 1, 2026
ISOVUE-M 300 is a mature, nonionic, low-osmolar iodinated contrast agent containing iopamidol at 300 mg iodine/mL. Bracco Diagnostics markets it for intrathecal procedures, including myelography and contrast-enhanced imaging of the central nervous system. Its commercial position depends on hospital purchasing contracts, radiology procedure volumes, supply reliability, and competition from other iopamidol and iodinated contrast products.
Product-level revenue, margin, and unit-volume data for ISOVUE-M 300 are not publicly disclosed. The product has no meaningful remaining exclusivity moat based on its active ingredient or core formulation. Financial performance is therefore more likely to reflect mature-product cash generation, institutional contracting, and manufacturing efficiency than patent-driven price protection.
What is ISOVUE-M 300 and how is it used?
ISOVUE-M 300 is an injectable formulation of iopamidol, a nonionic, water-soluble iodinated contrast medium. The "M" designation identifies the intrathecal product line. The 300 concentration contains 300 mg of organically bound iodine per milliliter.
The product is used primarily in neuroradiology and myelography. It is administered into the subarachnoid space to improve visualization during radiographic examinations of the spinal canal and related structures. The FDA label identifies indications that include lumbar, thoracic, cervical, and total-column myelography, as well as contrast-enhanced computed tomography of the head following intrathecal administration.[1]
ISOVUE-M 300 is distinct from intravenous ISOVUE products even though both contain iopamidol. Route of administration, formulation specifications, sterility requirements, labeling, and clinical risk management differ.
ISOVUE-M 300 product profile
| Attribute |
Detail |
| Active ingredient |
Iopamidol |
| Iodine concentration |
300 mg iodine/mL |
| Dosage form |
Sterile injectable solution |
| Route |
Intrathecal |
| Therapeutic category |
Nonionic iodinated contrast medium |
| Primary users |
Hospitals, radiology departments, imaging centers |
| Manufacturer |
Bracco Diagnostics Inc. |
| Main clinical use |
Myelography and related neuroradiologic imaging |
| Commercial status |
Mature marketed product |
| Biosimilar relevance |
None |
| Product-specific revenue |
Not publicly disclosed |
What is the FDA regulatory status of ISOVUE-M 300?
ISOVUE-M 300 is an FDA-approved prescription contrast agent with labeling governed through the FDA drug approval and postmarketing surveillance framework. The product is subject to requirements covering sterility, particulate control, container closure, manufacturing quality, adverse-event reporting, and administration precautions.[1]
The product carries warnings associated with intrathecal contrast administration, including risks of serious neurologic adverse reactions, seizures, infection, bleeding, and hypersensitivity. These risks make regulatory compliance and manufacturing consistency commercially important even after patent expiry.
The product is not a biologic and does not qualify for a biosimilar pathway. Competitive entry would occur through an approved generic or therapeutically equivalent contrast product, not through a 351(k) biosimilar application.
What is the Orange Book status of ISOVUE-M 300?
The commercial value of ISOVUE-M 300 is not supported by a current, high-value Orange Book patent estate comparable to newer branded medicines. Iopamidol is an old small-molecule contrast agent, and the principal composition and use concepts have long been exposed to generic competition.
The FDA Orange Book remains the controlling source for current listed patents and regulatory exclusivities.[2] For a mature product such as ISOVUE-M 300, the key commercial questions are whether an approved generic equivalent is actively marketed, whether the branded product has a distinct intrathecal formulation, and whether hospital contracts favor Bracco supply.
When does ISOVUE-M 300 lose exclusivity?
Core exclusivity for iopamidol and the original ISOVUE-M 300 product expired many years ago. The product was introduced in the United States during the 1980s, placing its original composition, clinical-use, and basic formulation protection well beyond the standard patent term.
A precise current patent-expiration date for an active ISOVUE-M 300 patent cannot be identified as a material commercial driver from publicly available FDA product information. The product should be analyzed as off-patent unless a specific later patent is shown to cover an enforceable formulation, manufacturing process, device, or use.
Exclusivity timeline
| Period |
Commercial significance |
| 1980s |
U.S. introduction of iopamidol-based ISOVUE products |
| Late 1980s to 1990s |
Core composition and early-use patent protection would have matured or expired |
| 2000s |
Product operated primarily as an established branded contrast agent |
| 2010s |
Market shaped by hospital contracting, generic competition, and imaging demand |
| 2020s |
Supply-chain resilience and contrast shortages became more important than exclusivity |
| Current |
Mature, patent-expired or effectively off-patent product economics |
What patents protect ISOVUE-M 300?
The relevant historical protection would have included patents covering iopamidol, nonionic iodinated contrast formulations, radiographic use, and manufacturing methods. Those protections are distinct from any later patent that might cover a specific container, delivery system, concentration, or process.
No publicly visible patent category appears capable of restoring broad market exclusivity for the basic ISOVUE-M 300 product. The active ingredient is established, the dosage form is conventional for injectable contrast media, and multiple competing iodinated agents are available.
What formulations are protected by ISOVUE-M 300 patents?
The commercially relevant formulation characteristics include:
- Iopamidol concentration of 300 mg iodine/mL.
- Sterile aqueous injectable solution.
- Low-osmolar nonionic contrast profile.
- Intrathecal labeling and administration controls.
- Packaging suitable for sterile hospital use.
These characteristics may have been addressed by historical patents or regulatory filings, but they do not create a durable modern barrier by themselves. A competitor would need to satisfy FDA requirements for product quality, sterility, labeling, and clinical comparability. The regulatory burden is more significant than the remaining composition patent risk.
Are there Paragraph IV challenges to ISOVUE-M 300?
Paragraph IV litigation is not the principal current risk for ISOVUE-M 300. Paragraph IV certifications typically matter when a branded drug has listed patents that block or delay ANDA approval. A mature iopamidol contrast product with expired foundational patents has limited incentive for high-value Paragraph IV litigation.
The more relevant competitive pathway is an ANDA or other approved generic route directed to iopamidol injection. The economic effect would be price competition rather than a contested launch against a valuable remaining patent.
No major, current Paragraph IV dispute is identified as a material determinant of ISOVUE-M 300's market outlook in the public record reviewed for this analysis.
Which companies compete with ISOVUE-M 300?
ISOVUE-M 300 competes within the hospital contrast-media market rather than in a conventional retail pharmacy market. The principal competitors are other nonionic iodinated agents used in radiology and neuroradiology.
Competitive products
| Company |
Product or platform |
Competitive relevance |
| GE HealthCare |
Omnipaque, iohexol |
Major nonionic iodinated contrast competitor; broad intravenous and intrathecal use |
| Bracco Diagnostics |
ISOVUE, iopamidol |
Internal portfolio and contracting strength |
| Guerbet |
Optiray, ioversol; Dotarem in MRI |
Competes in iodinated and broader imaging contrast categories |
| Bayer |
Ultravist, iopromide |
Major hospital contrast competitor in multiple markets |
| Generic manufacturers |
Iopamidol and other iodinated contrast injections |
Price-based competition where approved and commercially available |
Omnipaque is particularly relevant because iohexol has broad use in intrathecal imaging and computed tomography. The competitive decision is often made at the hospital formulary or health-system procurement level, where clinicians may accept therapeutic interchangeability among approved nonionic agents.
How strong is the patent estate for ISOVUE-M 300?
The patent estate is weak as a source of current pricing power. Its strength is better characterized as operational and regulatory rather than exclusivity-based.
Patent-strength assessment
| Factor |
Assessment |
Commercial effect |
| Active ingredient patent |
Low remaining value |
Iopamidol is an established compound |
| Core formulation |
Low to moderate |
Sterile manufacturing creates quality requirements but limited patent exclusivity |
| Intrathecal method of use |
Low remaining value |
Established clinical indication |
| Device or packaging claims |
Potentially limited |
May protect a specific presentation, not the active ingredient market |
| Manufacturing process |
Potentially relevant |
Can raise entry costs if difficult to replicate |
| Regulatory know-how |
Moderate |
Supports consistency, filings, and supply reliability |
| Brand and contracting |
Moderate |
Can preserve share after patent expiry |
| Broad exclusivity |
Low |
No apparent basis for monopoly pricing |
The most defensible commercial assets are manufacturing scale, validated sterile facilities, regulatory history, hospital relationships, and dependable supply. These assets can delay or weaken practical competition without preventing legal entry.
What manufacturing and intellectual-property barriers affect ISOVUE-M 300?
Sterile injectable contrast manufacturing is more demanding than production of an ordinary oral generic. Entrants must manage:
- Aseptic processing and terminal sterilization requirements.
- Endotoxin and particulate controls.
- Container-closure integrity.
- Iodinated raw-material sourcing.
- Concentration and osmolality control.
- Stability across storage conditions.
- Labeling for intrathecal administration.
- Batch-release testing.
- Drug-shortage reporting and supply continuity.
Iopamidol itself is commercially established, so raw scientific development risk is limited. The larger barriers are facility qualification, quality systems, regulatory approval, and the ability to supply hospitals at scale.
The 2022 GE HealthCare Omnipaque shortage illustrated the market's exposure to plant outages, logistics disruptions, and concentrated manufacturing capacity. The FDA reported temporary supply constraints affecting iodinated contrast media and issued communications concerning conservation and availability.[3] Shortages can improve the value of reliable suppliers, even when patents provide no protection.
What is the financial trajectory for ISOVUE-M 300?
ISOVUE-M 300 should be modeled as a mature institutional pharmaceutical product with stable but price-sensitive demand. Bracco does not publicly report standalone revenue for this SKU, so a product-level revenue forecast cannot be calculated from public filings.
Revenue drivers
The principal revenue drivers are:
- Volume of myelography and related neuroradiologic procedures.
- Bracco's share of hospital and integrated-delivery-network contracts.
- Availability of competing iopamidol and other nonionic contrast products.
- Temporary shortages affecting rival products.
- Product mix among 200, 300, and 370 mg iodine/mL concentrations.
- Pricing concessions required by group purchasing organizations.
- Changes in imaging protocols and substitution toward MRI or other diagnostic methods.
The overall market is more stable than a highly innovative pharmaceutical category because contrast media are embedded in routine diagnostic workflows. ISOVUE-M 300 demand is narrower than demand for broad intravenous CT agents because intrathecal use is a smaller procedure segment.
Likely financial phases
| Phase |
Revenue pattern |
Margin pattern |
| Launch and early adoption |
Rapid uptake as a branded approved product |
Stronger pricing and gross margin |
| Mature branded period |
Procedure-linked volume growth |
Gradual contracting pressure |
| Post-patent period |
Stable or declining unit price; share dependent on contracts |
Margin compression |
| Current mature period |
Low-to-moderate growth tied to procedures and supply conditions |
Manufacturing efficiency and mix become central |
| Shortage-driven periods |
Temporary volume and price opportunities |
Potentially higher revenue, but uneven and nonrecurring |
A reasonable strategic assumption is that long-term revenue growth is unlikely to exceed growth in the relevant imaging-procedure base unless Bracco gains share, benefits from competitor supply disruption, or expands distribution. Price increases are constrained by hospital procurement and therapeutic substitution.
What market dynamics determine generic launch risk?
Generic launch risk is moderate from a legal perspective and higher from a commercial perspective.
A generic entrant does not need to overcome a strong active-ingredient patent. It does need to prove that it can manufacture a sterile, consistent, regulatorily acceptable product and secure hospital purchasing access. The commercial challenge is often greater than the legal challenge because hospitals may prefer a supplier with an established shortage-response record and broad contrast-media availability.
Generic launch scenarios
| Scenario |
Effect on ISOVUE-M 300 |
| No active generic competitor |
Bracco retains pricing and formulary position, subject to contracting |
| One approved generic |
Selective price concessions and account-level share loss |
| Multiple generic suppliers |
Greater price erosion and possible tender-driven substitution |
| Competitor shortage |
Temporary share and volume gains for Bracco |
| Bracco supply disruption |
Rapid substitution risk and potential permanent account loss |
| Hospital formulary conversion |
Concentrated revenue loss within affected accounts |
Intrathecal labeling can reduce immediate substitution compared with intravenous contrast products, but hospitals often manage contrast agents through portfolio-level contracts. A supplier with several imaging products can use bundled procurement to defend share.
What litigation and settlement agreements affect ISOVUE-M 300?
No current patent litigation or settlement agreement is identified as a material driver of ISOVUE-M 300's commercial outlook. The product's age and the limited value of remaining exclusivity reduce the probability that patent litigation will determine market access.
Future disputes would be more likely to involve:
- Product liability and adverse-event claims.
- Manufacturing-quality allegations.
- Supply contracts.
- FDA compliance.
- Hospital procurement disputes.
- Trademark or trade-dress issues.
- ANDA approval or substitution questions for a specific generic entrant.
These matters would affect cost, supply, or account access, but they would not create a durable patent monopoly around iopamidol.
How does ISOVUE-M 300 compare with Omnipaque and other contrast agents?
ISOVUE-M 300's main advantage is its established iopamidol platform and Bracco's presence in diagnostic imaging. Omnipaque has broader recognition and extensive use across intrathecal, intravenous, and other radiographic procedures. Other agents compete through concentration options, clinical familiarity, supply reliability, and contracting.
| Dimension |
ISOVUE-M 300 |
Omnipaque |
Other iodinated agents |
| Active ingredient |
Iopamidol |
Iohexol |
Ioversol, iopromide and others |
| Intrathecal use |
Yes |
Yes |
Product-specific |
| Patent moat |
Limited |
Limited for mature presentations |
Generally limited for established agents |
| Key buying factor |
Contract, availability, familiarity |
Broad platform and supply footprint |
Price, supply, protocol fit |
| Biosimilar exposure |
None |
None |
None |
| Main risk |
Generic and contract substitution |
Supply and price competition |
Formulary displacement |
What is the geographic coverage of ISOVUE-M 300?
Bracco has an international diagnostic-imaging business, but product names, concentrations, indications, regulatory approvals, and pack sizes vary by country. U.S. commercial analysis should not be extended automatically to Europe, Asia-Pacific, or other jurisdictions.
Geographic performance depends on:
- Local approval of the iopamidol presentation.
- Hospital tender systems.
- National reimbursement and procurement rules.
- Availability of alternative contrast agents.
- Local manufacturing and distribution.
- Country-specific patent and data-exclusivity history.
Because ISOVUE-M 300 is an established product, geographic barriers are more likely to involve regulatory maintenance and distribution than active patent protection.
Key Takeaways
- ISOVUE-M 300 is a mature iopamidol-based intrathecal contrast agent marketed by Bracco Diagnostics.
- Its core composition and clinical-use exclusivity expired long ago, leaving little patent-driven pricing power.
- Product-level revenue and margin data are not publicly disclosed.
- Financial performance depends on procedure volumes, hospital contracts, manufacturing reliability, and competitor supply.
- The main competitors are Omnipaque, Optiray, Ultravist, and generic iodinated contrast products.
- Paragraph IV litigation and biosimilar risk are not central commercial issues.
- Sterile injectable manufacturing, regulatory compliance, and supply scale are more important barriers than patents.
- Generic entry would likely cause account-level price pressure and share loss rather than an abrupt market collapse.
- Shortages in competing contrast products can create temporary volume gains, but those benefits are not durable.
- ISOVUE-M 300 should be valued as a mature cash-generating hospital product, not as an exclusivity-protected growth asset.
FAQs
Is ISOVUE-M 300 still commercially important?
Yes, but its importance is concentrated in institutional imaging and intrathecal procedures. It is not a high-growth branded pharmaceutical asset.
Does ISOVUE-M 300 have biosimilar competition?
No. Iopamidol is a small-molecule drug, so competitive products are generics or other approved contrast agents rather than biosimilars.
Can a generic manufacturer launch iopamidol injection?
A manufacturer may pursue an FDA-approved generic pathway if it satisfies applicable quality, bioequivalence, labeling, and manufacturing requirements. Commercial launch also depends on hospital contracts and supply capacity.
Is ISOVUE-M 300 interchangeable with Omnipaque?
Both products are nonionic iodinated contrast agents with intrathecal applications, but interchangeability depends on the specific product labeling, institutional protocol, concentration, clinical judgment, and procurement policy.
Does ISOVUE-M 300 have a major remaining patent barrier?
No major broad patent barrier is apparent for the established iopamidol product. Any residual protection would more likely concern a narrow formulation, packaging, process, or presentation claim.
References
- U.S. Food and Drug Administration. (n.d.). ISOVUE-M (iopamidol injection) prescribing information.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Food and Drug Administration. (2022). FDA updates on supply of iodinated contrast media and conservation measures.
- Bracco Diagnostics Inc. (n.d.). ISOVUE product information.
- U.S. National Library of Medicine. (n.d.). DailyMed: ISOVUE-M iopamidol injection labeling.
